The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Blueprint Medicines; Bristol Myers Squibb Foundation; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).
 
Cesar Serrano
Honoraria - Deciphera; PharmaMar
Consulting or Advisory Role - Blueprint Medicines; Captor Therapeutics Inc; Cogent Biosciences; Deciphera; Immunicum
Research Funding - Karyopharm Therapeutics (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Pfizer; PharmaMar
 
Sebastian Bauer
Honoraria - Bayer; Deciphera; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
David Gómez-Peregrina
No Relationships to Disclose
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Robin L. Jones
Consulting or Advisory Role - Athenex; Blueprint Medicines; Deciphera; Eisai; PharmaMar; TRACON Pharma
Other Relationship - Deciphera
 
Piotr Rutkowski
No Relationships to Disclose
 
Olivier Mir
Employment - Amgen
Stock and Other Ownership Interests - Amgen; Amplitude Surgical; Ipsen; Transgene
Honoraria - Roche
Consulting or Advisory Role - Janssen; Lilly; Lundbeck; Pfizer; Roche
Speakers' Bureau - Lilly; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Ipsen
Travel, Accommodations, Expenses - Pfizer; Roche
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Novartis; Theseus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; Ayala Pharmaceuticals; Bayer; C4 Therapeutics; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; Foghorn Therapeutics; Kowa Pharmaceutical; Lilly; Medpacto; Mundipharma; Servier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Kate Newberry
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Alexandra Grassian
Employment - Blueprint Medicines
 
Stephen G. Miller
Employment - Blueprint Medicines
 
Hongliang Shi
Employment - Blueprint Medicines
 
Patrick Schöffski
Honoraria - Blueprint Medicines
Consulting or Advisory Role - Adcendo; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Ellipses Pharma; Exelixis; Merck; PharmaMar; SQZ Biotechnology; Studiecentrum voor Kernenergie (SCK CEN); Transgene
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)
 
Maria A. Pantaleo
No Relationships to Disclose
 
Margaret von Mehren
Consulting or Advisory Role - deciphera; GlaxoSmithKline
Research Funding - ASCO (Inst); Deciphera (Inst); Genmab (Inst); Gradalis (Inst); Novartis (Inst); Solaris Health (Inst)
Patents, Royalties, Other Intellectual Property - cell line
Other Relationship - NCCN
 
Jonathan C. Trent
Consulting or Advisory Role - Agios; Bayer; Blueprint Medicines; C4 Therapeutics; Daiichi Sankyo; Deciphera; Epizyme; Janssen; Lilly; Novartis
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); Merck (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG